实时定量PCR检测白血病融合基因的应用研究  

Real-Time Fluorescence Quantitative PCR Detection of Fusion Genes in Leukemia Diagnosis

作　　者：郑慧丽[1] 于慧洋[2] 许霁虹[2] 刘立峰[1] 王雁[1] 郭晓霞[1] 

机构地区：[1]黑龙江省齐齐哈尔市第一医院检验科,161005 [2]黑龙江省齐齐哈尔市第一医院血液科,161005

出　　处：《中华全科医学》2011年第7期1126-1128,1163,共3页Chinese Journal of General Practice

摘　　要：目的探讨实时荧光定量RT-PCR(RQ-PCR)检测融合基因在慢性粒细胞性白血病(CML)及急性早幼粒细胞白血病(APL)诊疗中的应用价值。方法采用RQ-PCR方法,对15例拟诊CML和17例拟诊APL的患者,在诊断及治疗过程中分别进行融合基因BCR/ABL、PML/RARa的检测,并且观察CML经羟基脲+干扰素(Hu+IFNα)与伊马替尼(IM)不同药物治疗的疗效差别。结果 15例拟诊CML患者中12例经融合基因检测确定诊断;17例拟诊APL患者中15例经融合基因检测确定诊断。动态观察,两种疾病在治疗的6个月、12个月时融合基因表达量明显下降,与初诊比较差异有统计学意义(P<0.01),其中CML两种不同治疗方案间差别显著(P<0.05)。两种疾病在血液学进展或复发前可发现融合基因显著升高。结论融合基因检测对于CML、APL的诊断、疗效观察和微小残留病的监测有重要价值。Objective To study the application of real time quantitative RT-PCR（RQ-PCR） detection of fusion gene in chronic myeloid leukemia（CML） and acute promyelocytic leukemia（APL）.Methods 15 cases of suspected CML patients and 17 cases of suspected APL patients were diagnosed by RQ-PCR method respectively,in the process of diagnosis and treatment,the fusion gene BCR/ABL and PML/RARa were detected and differences in the therapeutic effect of CML hydroxyurea＋interferon（Hu＋IFNα） and imatinib（IM） was observed.Results Among 15 suspected patients,12 cases were diagnosed as CML by fusion gene detection;among 17 suspected patients,15 cases were diagnosed as APL this method.6 and 12 months post-treatment,fusion gene expression decreased significantly,the difference was significant when compared with the first visit（P0.01）.The significant increase of fusion gene can be found prior to hematological progress or the diseases relapse.Conclusion The detection of fusion gene had an important value in CML and APL diagnosis,observation and monitoring of minimal residual disease.

关 键 词：基因 聚合酶链反应 慢性粒细胞白血病 急性早幼粒细胞白血病 

分 类 号：R733.7[医药卫生—肿瘤]